Overview
A colloidal system of semisolid hydrocarbons obtained from petroleum. It is used as an ointment base, topical protectant, and lubricant.
Indication
For use as an over the counter skin protectant . Commonly used to treat diaper rash and chapped lips .
Associated Conditions
- Dermabrasion
- Diaper Rash
- Dry Skin
- Itching of the perianal area
- Pain
- Skin Irritation
- Burning skin sensation
- Minor burns
Research Report
A Comprehensive Monograph on Petrolatum (CAS 8009-03-8): From Physicochemical Properties to Clinical and Cosmetic Applications
I. Executive Summary
Petrolatum is a complex, semi-solid mixture of hydrocarbons derived from petroleum, universally recognized for its exceptional occlusive and emollient properties. This monograph provides a comprehensive analysis of Petrolatum, identified by DrugBank ID DB11058 and CAS Number 8009-03-8, covering its chemical identity, manufacturing processes, mechanism of action, therapeutic and cosmetic applications, safety profile, and global regulatory status.
A central theme of this report is the paramount importance of the refining process in determining the quality and safety of the final product. The analysis establishes a clear distinction between highly refined cosmetic and pharmaceutical grades of Petrolatum, which are demonstrably safe for human use, and less-refined industrial grades that may pose health risks due to potential contamination with polycyclic aromatic hydrocarbons (PAHs). The safety, efficacy, and regulatory acceptance of Petrolatum are therefore entirely contingent on its purity.
In the United States, the Food and Drug Administration (FDA) approves Petrolatum as an over-the-counter (OTC) skin protectant, and it serves as a ubiquitous excipient and active ingredient in a vast array of dermatological, ophthalmic, and anorectal preparations. Concurrently, it is a cornerstone ingredient in the global cosmetics and personal care industry.
This report also details a significant paradigm shift in the scientific understanding of Petrolatum. Long considered a chemically inert barrier, recent clinical evidence reveals it possesses bioactive properties, actively modulating the skin's innate immune response and promoting the expression of key epidermal differentiation proteins. This modern understanding provides a molecular basis for its profound efficacy in treating barrier-deficient skin conditions.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
|---|---|---|---|---|---|
2022/04/29 | Not Applicable | Completed | |||
2022/04/06 | Phase 2 | UNKNOWN | |||
2021/07/06 | Phase 2 | Completed | |||
2019/08/28 | Phase 2 | UNKNOWN | |||
2019/04/16 | Phase 1 | Completed | |||
2019/01/24 | Phase 4 | UNKNOWN | |||
2018/06/19 | Early Phase 1 | Recruiting | |||
2016/11/18 | Phase 2 | Completed | |||
2015/07/01 | Phase 4 | Completed | |||
2015/02/04 | Phase 1 | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
|---|---|---|---|---|---|
| Jack Black L.L.C. | 66738-171 | TOPICAL | 40.2 g in 100 mL | 9/5/2025 | |
| MY IMPORTS USA LLC | 51628-4248 | TOPICAL | 53.4 g in 100 g | 8/22/2025 | |
| Harris Teeter | 72036-069 | TOPICAL | 1 g in 1 g | 3/3/2025 | |
| FAMILY DOLLAR STORES, INC | 55319-952 | TOPICAL | 410 mg in 1 g | 5/27/2025 | |
| Jack Black L.L.C. | 66738-161 | TOPICAL | 40.2 g in 100 mL | 9/5/2025 | |
| Pharmaceutics Corporation | 49430-053 | TOPICAL | 30 mg in 1 1 | 3/20/2015 | |
| REVLON | 10967-673 | TOPICAL | 56.8 mg in 1 g | 8/1/2025 | |
| MY IMPORTS USA LLC | 51628-4249 | TOPICAL | 100 g in 100 g | 8/24/2025 | |
| Amazon.com Services LLC | 72288-180 | TOPICAL | 410 mg in 1 g | 9/15/2025 | |
| Walgreens | 0363-0712 | TOPICAL | 99 g in 100 g | 7/13/2025 |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
|---|---|---|---|
| No EMA approvals found for this drug. | |||
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No HSA approvals found for this drug. | |||||
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
|---|---|---|---|---|---|
| No NMPA approvals found for this drug. | |||||
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
|---|---|---|---|---|---|
| No PPB approvals found for this drug. | |||||
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
|---|---|---|---|---|---|
| No TGA approvals found for this drug. | |||||
Health Canada Drug Approvals
Approved Product | Company | DIN | Dosage Form | Strength | Market Date |
|---|---|---|---|---|---|
| PROTECTIVE OINTMENT | 02325578 | Ointment - Topical | 98.79 % / W/W | 6/4/2010 | |
| WHITE PETROLEUM JELLY ULTRA MOISTURIZER | belvedere international inc. | 02320797 | Ointment - Topical | 100 % | 5/1/2009 |
| FORMULATION R HEMORRHOIDAL OINTMENT | g&w laboratories inc. | 02246389 | Ointment - Topical | 71.9 % | N/A |
| HEEL BALM | tanta pharmaceuticals inc | 02371561 | Cream - Topical | 9.88 % | N/A |
| PETROLATUM JELLY UNSCENTED | cellchem pharmaceuticals inc. | 02322757 | Ointment - Topical | 100 % / W/W | N/A |
| COSMACARE WHITE PETROLATUM OINTMENT USP | cosmaceutical research lab inc. | 02368765 | Ointment - Topical | 100 % | N/A |
| WHITE PETROLEUM JELLY 100% BP | h.j. sutton industries ltd. | 00745790 | Ointment - Topical | 100 % | 12/31/1989 |
| PETROLEUM JELLY SCENTED | 02386623 | Ointment - Topical | 99.6 % / W/W | 6/8/2013 | |
| MEDICATED LIPBALM | norwood packaging ltd | 02286866 | Stick - Topical | 39.0 % | N/A |
| NURSING CREAM | e.t. browne drug co., inc. | 02239629 | Cream - Topical | 95.96 % | 12/15/1999 |
CIMA AEMPS Drug Approvals
Approved Product | Company | Registration Number | Pharmaceutical Form | Prescription Type | Status |
|---|---|---|---|---|---|
| No CIMA AEMPS (Spain) approvals found for this drug. | |||||
Philippines FDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Philippines FDA approvals found for this drug. | |||||
Saudi SFDA Drug Approvals
Approved Product | Company | License Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Saudi SFDA approvals found for this drug. | |||||
Malaysia NPRA Drug Approvals
Approved Product | Company | Registration Number | Dosage Form | Strength | Approval Date |
|---|---|---|---|---|---|
| No Malaysia NPRA approvals found for this drug. | |||||
UK EMC Drug Information
Medicine Name | MA Holder | MA Number | Pharmaceutical Form | Active Ingredient | Authorization Date |
|---|---|---|---|---|---|
| No UK EMC drug information found for this drug. | |||||
Help Us Improve
Your feedback helps us provide better drug information and insights.
